Business Wire

STC calls on ADVA’s NFV suite for uCPE services

28.1.2021 11:00:00 EET | Business Wire | Press release

Share

ADVA (FSE: ADV) today announced that the Saudi Telecom Company (STC) is rolling out on-demand virtual services using ADVA’s Ensemble suite of network functions virtualization (NFV) technologies. The new universal CPE (uCPE) offering is built on the Dell EMC Networking Virtual Edge Platform (VEP) 1405 series running ADVA’s Ensemble Edge Cloud NFV suite. Enterprise customers of STC, the largest IT service provider in the Middle East, will be able to quickly and easily access virtual services, including routing, firewall, WAN optimization, IoT and voice applications. With the industry’s largest ecosystem of virtual network functions (VNFs) to choose from, managed service customers can automatically enable new applications and services without any financial risk.

“Today’s enterprises need to be agile. They require the freedom to mix and match the latest cloud technologies to seize new revenue opportunities in an instant. That’s what our new uCPE service is all about. It eliminates vendor lock-in and lets our clients experiment with best-in-class solutions that fit their specific needs and ambitions,” said Fahad A. Alhajeri, VP, digital solutions, STC. “By giving our customers quick and secure access to an unrivalled range of multi-vendor virtual technologies, we’re unleashing the full potential of businesses in this region. With the help of ADVA’s Ensemble NFV technology, we’re forging a path for our customers to a cloud-based future of on-demand services and rapid innovation.”

STC’s new uCPE offering enables businesses across the Middle East to select virtual products from the Ensemble Harmony Ecosystem, a unique multi-vendor environment with unparalleled variety and choice. It’s built on the Dell EMC Networking VEP 1405 series, a compact, low-power uCPE appliance purpose-built to host VNFs and ideal for demanding SD-WAN applications. With ADVA’s Ensemble Connector as the NFVI platform, multiple VNFs can run on a single uCPE. Other key components include Ensemble Orchestrator and Virtualization Director, which provide a simple and effective management and orchestration (MANO) architecture, empowering STC to roll out secure virtualized services at scale.

“STC’s uCPE service is ideal for connecting the enterprise to the cloud. Now businesses throughout the Middle East can leverage the power of virtualization and choose from the market’s widest range of onboarded commercial VNFs,” commented James Buchanan, GM, Edge Cloud, ADVA. “Our Ensemble suite’s MANO capabilities support the rollout of secure virtualized service across multiple locations with complete flexibility and scale. And, thanks to our Ensemble Connector’s zero-touch provisioning, STC can ship uCPE to a customer site and provision it securely with no need for technicians. With such rapid deployments and agile service creation at the network edge, STC is leading the way to the managed services of tomorrow.”

“By utilizing our Virtual Edge Platform 1405 series and ADVA’s Ensemble software, STC is giving its customers a simple way to respond to shifting industry demand,” said Drew Schulke, VP, Dell EMC Networking, Dell Technologies. “Working with ADVA, we’re empowering STC and its customers to digitalize their infrastructures. Now they can deploy solutions at the click of a mouse and harness advanced tools for boosting security, reducing costs and improving end-user customer experience.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About STC
“Solutions by STC” is one of the largest technology and communications services providers in the Middle East. The company has a range of products and services that address the needs of consumers and businesses of all sizes. Solutions by STC has continued to build upon its core telecom position and offers innovative digital services and solutions for enterprises, including cloud and infrastructure services, network and security management services, Big Data and analytics solutions, and Internet of Things (IoT) solutions (such as fleet/asset management and mobile point-of-sale solutions). These solutions complement stc’s considerable systems integration capabilities across several industries. www.solutions.com.sa.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye